Cover Image
Market Research Report

Personalized Medicines In Oncology Market -By Tumor (Genomics, Proteomics, Metabolomics) End User (Hospitals, Research Centers, Governmental institutions) Technology (Next-Generation Sequencing, PCR, Others) By Occurrence- Forecast(2016-2021)

Published by IndustryARC Product code 409893
Published Content info 140 Pages
Delivery time: 1-2 business days
Price
Back to Top
Personalized Medicines In Oncology Market -By Tumor (Genomics, Proteomics, Metabolomics) End User (Hospitals, Research Centers, Governmental institutions) Technology (Next-Generation Sequencing, PCR, Others) By Occurrence- Forecast(2016-2021)
Published: January 14, 2016 Content info: 140 Pages
Description

A Personalized medicine application has the largest network, mainly due to high demand for the effective cancer treatment. Apart from the huge potential of the market in personalized medicine and diagnostic segments; it also has a strong value and the vast expansion opportunities in its application such as biomarker, discovery, cancer and research applications. A number of new tools and services are offered by the various biotechnology medical companies for cancer/tumor profiling which is greatly served a cancer screening and the diagnostic. These tools and services are speeding up the development in the cancer therapeutics field and help in boosting the growth of the personalized medicine market.

A significant tool to achieve Personalized Medicine is the availability of repositories of freely accessible databases. Large databases are formed containing information from genomic, transcriptomic, and proteomic analyses which is available for global access and data processing. Some of these include the Cancer Genome Anatomy Project, the Single Nucleotide Polymorphism Database, in addition to many others. Bioinformatics algorithms can then be used to integrate a patient's clinical information and the genetic profiles of their tumor to predict the relationships of certain molecular changes to the cancer.

Standardization of Personalized medicine includes several characteristics including the type of sample to be analyzed, the suitable methods of sample collection and storage, the selection of the target genes/proteins to be tested, the platform to be used, best experimental conditions, and the interpretation of tests. There are specific quality standards for different laboratories, and test validations will be required with external quality assurance protocols.

There are different approaches and tools available for molecular Personalized Medicine testing. A large array of techniques can be used for Personalized Medicine. Commonly used techniques include PCR, fluorescence in situ hybridization and sequencing. Recently, the completion of the human genome project opened a new opportunities for Personalize Medicine analysis by using high-throughput analysis. These include microarray, mass spectrometry, second-generation sequencing, array comparative genomic hybridization, and high-throughput SNP analysis, among others. A common trend among these tools is their ability to simultaneously analyze hundreds or thousands of targets. This multipara metric approach is likely to improve the sensitivity, specificity, and accuracy of new biomarkers. In addition to acceleration of biomarker discovery, high-throughput analysis allows a better understanding of interaction between different molecules in the pathogenesis of cancer.

The overall market generated revenue of $xx m in 2015 and is expected to grow with CAGR of xx% throughout the forecast period to generate $xx m by 2021. The Major players are focusing on marketing their products in emerging markets such as India, Japan, Brazil, and China. Currently Americas and Europe region dominate the overall market by contributing to xx% of the overall revenue. These regions are growing with CAGR of xx% and xx% respectively throughout the forecast period.

The Key biotechnology and pharmaceutical companies such as Caris Life Sciences (U.S.), Proteome Sciences PLC (U.K.), Life Technologies (U.S.), Boreal Genomics, Inc. (U.S.), Oxford Gene Technology Ltd. (OGT) (U.K.), and Precision Therapeutics, Inc. (U.S.), among others, are undertaking various strategically decisions such as collaborating and partnering with each other as well as with research universities to develop cancer profiling products.

Table of Contents

Table of Contents

1. Market Overview

2. Executive Summary

3. Personalized Medicines In Oncology Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. Personalized Medicines In Oncology Forces

  • 4.1. Market Drivers
  • 4.2. Market Constraints & Challenges
  • 4.3. Attractiveness of the Personalized Medicines In Oncology Market
    • 4.3.1. Power of Suppliers
    • 4.3.2. Threats From New Entrants
    • 4.3.3. Power of Buyer
    • 4.3.4. Threat From Substitute Product
    • 4.3.5. Degree of Competition

5. Personalized Medicines In Oncology -Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunity Analysis
  • 5.4. Product Life Cycle
  • 5.5. Suppliers and Distributors

6. Personalized Medicines In Oncology- By Tumore Type

  • 6.1. Genomics
  • 6.2. Proteomics
  • 6.3. Metabolomics
  • 6.4. Epigenetics

7. Personalized Medicines In Oncology- By Service

  • 7.1. Molecular Oncopathology
  • 7.2. Genome Diagnostics
  • 7.3. Radiation Therapy
  • 7.4. Oncology Testing
  • 7.5. Chemotherapy
  • 7.6. Others

8. Personalized Medicines In Oncology- By Occurrence

  • 8.1. Colorectal/ stomach/ esophageal
  • 8.2. Ovarian
  • 8.3. Lung
  • 8.4. Brest
  • 8.5. Sarcoma
  • 8.6. Pancreatic
  • 8.7. Cancer
  • 8.8. Mesothelioma
  • 8.9. Others

9. Personalized Medicines In Oncology- By Technology

  • 9.1. Next-Generation Sequencing
  • 9.2. Fluorescence/ Chromogenic In Situ Hybridization
  • 9.3. Immunohistochemistry
  • 9.4. Microarray
  • 9.5. Quantitative PCR
  • 9.6. High Throughput SNP Analysis
  • 9.7. Others

10. Personalized Medicines In Oncology- By End User

  • 10.1. Research Centers
  • 10.2. Governmental Institutions
  • 10.3. Hospitals
  • 10.4. others

11. Personalized Medicines In Oncology- Geography

  • 11.1. Americas
    • 11.1.1. U.S.
    • 11.1.2. Canada
    • 11.1.3. Brazil
    • 11.1.4. Others
  • 11.2. Europe
    • 11.2.1. U.K.
    • 11.2.2. Germany
    • 11.2.3. Italy
    • 11.2.4. France
    • 11.2.5. Others
  • 11.3. Asia Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. Australia & New Zealand
    • 11.3.4. Others
  • 11.4. Rest of The World (RoW)
    • 11.4.1. Middle East
    • 11.4.2. Africa

12. Personalized Medicines In Oncology Entropy

  • 12.1. New Product Developments
  • 12.2. Product Launches, JVs, Mergers and Acquisitions

13. Company Profiles

  • 13.1. Agendia Nv
  • 13.2. Allere Laboratory
  • 13.3. Alpha Genomix
  • 13.4. Ariana Pharma
  • 13.5. Biocrates
  • 13.6. Biodiscovery
  • 13.7. Biotheranostics
  • 13.8. Boreal Genomics, Inc.
  • 13.9. Caris Life Sciences
  • 13.10. Chordoma Foundation
  • 13.11. CompanionDx
  • 13.12. Cypher Genomics
  • 13.13. deCode Genetics
  • 13.14. Diploid
  • 13.15. DNA Link
  • 13.16. Edge Bio
  • 13.17. Foundation Medicine
  • 13.18. Fulgent Diagnostics
  • 13.19. Gene TLC
  • 13.20. GenebyGene
  • 13.21. Genomic Engenharia Molecular
  • 13.22. Genomic Health, Inc.
  • 13.23. Illumina, Inc.
  • 13.24. Life Technologies Corporation
  • 13.25. MapMyGenome

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

Back to Top